XML 256 R81.htm IDEA: XBRL DOCUMENT
v3.25.2

Related parties (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2025
Related parties |
Schedule of key management remuneration | Executive directors’ remuneration and benefits
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | S Baloyi³ |  | WP Bruns4 | ​ | FR Grobler5 |  | VD Kahla |  | HA Rossouw6
​ |  | 2025 |  | 2024 |  | 2025 |  | 2024 | ​ | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024
Executive Directors |  | R’000 |  | R’000 |  | R’000 |  | R’000 |  | R’000 |  | R’000 |  | R’000 |  | R’000 |  | R’000 |  | R’000
Salary |  | 12 514 |  | 2 503 |  | 5 982 | ​ | — | ​ | — |  | 10 615 |  | 8 499 |  | 8 216 |  | 1 336 |  | 7 901
Risk and Retirement funding |  | 1 276 |  | 385 |  | 788 | ​ | — | ​ | — |  | — |  | 382 |  | 388 |  | 151 |  | 894
Vehicle benefit |  | 300 |  | 75 |  | — | ​ | — | ​ | — |  | — |  | — |  | — |  | — |  | —
Healthcare |  | 160 |  | 36 |  | 147 | ​ | — | ​ | — |  | 117 |  | 147 |  | 132 |  | — |  | —
Taxable fringe benefits |  | 96 | ​ | 7 |  | 17 | ​ | — | ​ | — |  | 55 |  | 606 |  | 570 |  | — |  | 38
Total salary and benefits |  | 14 346 |  | 3 006 |  | 6 934 | ​ | — | ​ | — |  | 10 787 |  | 9 634 |  | 9 306 |  | 1 487 |  | 8 833
Annual short-term incentive1 | ​ | 11 213 | ​ | 1 473 | ​ | 3 984 | ​ | — | ​ | — | ​ | 4 882 | ​ | 4 360 | ​ | 2 579 | ​ | — | ​ | 2 804
Long-term incentive gains2 |  | 353 |  | 2 675 |  | 387 | ​ | — | ​ | — |  | 5 492 |  | 3 569 |  | 2 794 |  | — |  | —
Total annual remuneration |  | 25 912 |  | 7 154 |  | 11 305 | ​ | — | ​ | — |  | 21 161 |  | 17 563 |  | 14 679 |  | 1 487 |  | 11 637
​
| 1 | Short-term incentives approved based on the Group results for 2025 and payable in the 2026 financial year. Incentives are calculated as a percentage of total guaranteed package/base salary as at 30 June 2025 x role category % x [(Group STI achievement x 80%) + (Individual Performance Achievement x 20%)] – fatality penalty.
| 2 | Long-term incentives gains for 2025 includes the Restricted LTI awards made on 4 December 2020 and the annual and on-appointment awards made between 6 September 2022 and 10 November 2022. The illustrative amount is calculated in terms of the number of LTIs x Corporate performance target achieved where relevant (between 84% and 95%) x June 2025 average share price. The actual vesting date for the awards is between 6 September 2025 and 4 December 2025 subject to the company being in an open period. Dividend equivalents accrue at the end of the vesting period, to the extent that the LTIs vest. 50% of the vested LTIs and accrued dividends will be released in 2026 and the balance in 2028, subject to the rules of the LTI plan. As there are no further performance conditions attached to the balance of the 50%, the full amount is disclosed in the single figure table.
| 3 | Mr Baloyi was appointed as President and CEO from 1 April 2024. His prior year remuneration was apportioned between his 9 months’ service as a Prescribed Officer and 3 months’ service as President and CEO.
| 4 | Mr Bruns was appointed as CFO from 1 September 2024. His current remuneration has been apportioned in respect of his 10-month service as an Executive Director.
| 5 | Mr Grobler stepped down from the position of President and CEO on 31 March 2024.
| 6 | Mr Rossouw stepped down as executive director and CFO effective 31 August 2024. All unvested LTIs were forfeited upon his resignation.
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Executive directors’ unvested LTI holdings (number and intrinsic value) for 2025
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | S Baloyi |  | WP Bruns | ​ | VD Kahla | ​ | HA Rossouw
​ |  | ​ |  | Intrinsic |  | ​ | ​ | Intrinsic | ​ | ​ |  | Intrinsic |  | ​ |  | Intrinsic
​ | ​ | Number | ​ | value1 | ​ | Number |  | value1 |  | Number |  | value1 |  | Number |  | value1
Executive Directors |  | ​ |  | R’000 |  | ​ | ​ | R’000 | ​ | ​ |  | R’000 |  |  |  | R’000
Balance at beginning of the year |  | 79 004 |  | 10 910 |  | — | ​ | — | ​ | 180 870 |  | 24 978 |  | 76 820 |  | 10 609
Awards granted2 |  | 152 150 |  | 22 509 |  | 110 950 | ​ | 14 885 | ​ | 65 915 |  | 9 751 |  | — |  | —
Change in value1 |  | — |  | (14 930) |  | — | ​ | (9 555) | ​ | — |  | (14 939) |  | — |  | (40)
Effect of corporate performance targets |  | (1 988) |  | (196) |  | (392) | ​ | (39) | ​ | (3 420) |  | (338) |  | — |  | —
Dividend equivalents |  | 6 543 |  | 646 |  | 2 241 | ​ | 221 | ​ | 7 909 |  | 781 |  | — |  | —
Awards settled3 |  | (18 191) |  | (1 807) |  | (6 027) | ​ | (689) | ​ | (28 498) |  | (2 687) |  | — |  | —
Awards forfeited4 | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | (76 820) | ​ | (10 569)
Effect of changes in Executive Directors |  | — |  | — |  | 60 986 | ​ | 8 390 | ​ | — |  | — |  | — |  | —
Balance at the end of the year5 |  | 217 518 |  | 17 132 |  | 167 758 | ​ | 13 213 | ​ | 222 776 |  | 17 546 |  | — |  | —
| 1 | Intrinsic values at the beginning and end of the year have been determined using the closing price of:
30 June 2025 R78,76 30 June 2024 R138,10 Change in intrinsic value for the year results from changes in share price.
| 2 | LTIs granted on 26 August 2024 and 15 November 2025 (WP Bruns only on his appointment).
| 3 | Long-term incentives settled represent long-term incentives that vested with reference to the group results for 2024 that was settled in the 2025 financial year. The difference between the long-term incentive gains disclosed in 2024 and the amount settled in 2025 is due to difference in actual share price at vesting date and the share price at date of disclosure. 50% of the award that vested in 2025 is still subject to a continued employment period of two years.
| 4 | Mr Rossouw resigned effective 31 August 2024. In terms of the LTI plans rules his awards lapsed on resignation.
| 5 | Includes a total of 22 761 award issued in FY21 for which the renewable energy CPT has been deferred up to 31 December 2026.
Prescribed Officers’ remuneration and benefits ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | S Baloyi3 | ​ | V Bester4 | ​ | AGM Gerber5 | ​ | BV Griffith6
​ | ​ | 2025 | ​ | 2024 | ​ | 2025 | ​ | 2024 | ​ | 2025 | ​ | 2024 | ​ | 2025 | ​ | 2024
Prescribed Officers |  | R’000 |  | R’000 |  | R’000 |  | R’000 |  | R’000 |  | R’000 |  | R’000 |  | R’000
Salary |  | — |  | 4 352 |  | 6 044 |  | 1 386 |  | 9 375 |  | 1 943 |  | — |  | 9 594
Risk and Retirement funding |  | — |  | 857 |  | 920 |  | 211 |  | 873 |  | 51 |  | — |  | 2 012
Vehicle benefit |  | — |  | 225 |  | — |  | — |  | 308 |  | 75 |  | — |  | —
Healthcare |  | — |  | 106 |  | 121 |  | 28 |  | 104 |  | 21 |  | — |  | 311
Taxable fringe benefits7 |  | — |  | 20 |  | 100 |  | 1 001 |  | 217 |  | 113 |  | — |  | 469
Total salary and benefits |  | — |  | 5 560 |  | 7 185 |  | 2 626 |  | 10 877 |  | 2 203 |  | — |  | 12 386
Annual short-term incentive1 |  | — |  | 4 418 |  | 3 549 |  | 479 |  | 4 867 |  | — |  | — |  | 2 730
Long-term incentive gains2 |  | — |  | — |  | 119 |  | 1 086 |  | — |  | — |  | — |  | 2 935
Total annual remuneration |  | — |  | 9 978 |  | 10 853 |  | 4 191 |  | 15 744 |  | 2 203 |  | — |  | 18 051
| 1 | Short-term incentives approved based on the Group results for 2025 and payable in the 2026 financial year. Incentives are calculated as a percentage of total guaranteed package/base salary as at 30 June 2025 x role category % x [(Group STI achievement x 80%) + (Individual Performance Achievement x 20%)] – fatality penalty.
| 2 | Long-term incentives gains for 2025 includes the Restricted LTI awards made on 4 December 2020 and the annual and on-appointment grant awards made between 6 September 2022 and 9 May 2023. The illustrative amount is calculated in terms of the number of LTIs x Corporate performance target achieved where relevant (between 84% and 96%) x June 2025 average share price. The actual vesting date for the awards is between 6 September 2025 and 9 May 2026 subject to the company being in an open period. Dividend equivalents accrue at the end of the vesting period, to the extent that the LTIs vest. 50% of the vested LTIs and accrued dividends will be released in 2026 and the balance in 2028, subject to the rules of the LTI plan. As there are no further performance conditions attached to the balance of the 50%, the full amount is disclosed in the single figure table.
| 3 | Mr Baloyi was appointed as President and CEO from 1 April 2024. His prior year remuneration was apportioned between his 9 months’ service as a Prescribed Officer and 3 months’ service as President and CEO.
| 4 | Mr Bester was appointed as EVP: Energy Operations and Projects from 1 April 2024. His prior year earnings include a last tranche of R 1 million offered as a buy-out on his appointment and paid in May 2024, as part of a staggered buy-out agreement to partially compensate for variable pay forfeited upon resignation from his previous employer.
| 5 | Ms Gerber was appointed on 15 April 2024 as EVP: International Chemicals on a German employment contract, payable in Euros. Other Benefits in the prior year include accommodation costs for a three month period, per her contract of employment.
| 6 | Mr Griffith stepped down as EVP Chemicals business on 14 April 2024.
| 7 | Taxable Fringe Benefits include optional security services and private chauffer trips on which fringe benefit tax is levied.
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | C Herrmann3 | ​ | BP Mabelane4 | ​ | CK Mokoena
​ | ​ | 2025 | ​ | 2024 | ​ | 2025 | ​ | 2024 | ​ | 2025 | ​ | 2024
Prescribed Officers |  | R’000 |  | R’000 |  | R’000 |  | R’000 |  | R’000 |  | R’000
Salary |  | 7 969 |  | 1 845 |  | — |  | 6 153 |  | 6 915 |  | 6 655
Risk and Retirement funding |  | 595 |  | 142 |  | — |  | 290 |  | 327 |  | 363
Vehicle benefit |  | 252 |  | — |  | — |  | — |  | — |  | —
Healthcare |  | 224 |  | 25 |  | — |  | 47 |  | 174 |  | 157
Taxable fringe benefits5 |  | 2 634 |  | 648 |  | — |  | 22 625 |  | 72 |  | 21
Total salary and benefits |  | 11 674 |  | 2 660 |  | — |  | 29 115 |  | 7 488 |  | 7 196
Annual short-term incentive1 |  | 3 894 |  | 577 |  | — |  | — |  | 3 637 |  | 2 119
Long-term incentive gains2 |  | 637 |  | 2 062 |  | — |  | — |  | 2 931 |  | 2 295
Total annual remuneration |  | 16 205 |  | 5 299 |  | — |  | 29 115 |  | 14 056 |  | 11 610
| 1 | Short-term incentives approved based on the Group results for 2025 and payable in the 2026 financial year. Incentives are calculated as a percentage of total guaranteed package/base salary as at 30 June 2025 x role category % x [(Group STI achievement x 80%) + (Individual Performance Achievement x 20%)] – fatality penalty.
| 2 | Long-term incentives gains for 2025 includes the Restricted LTI awards made on 4 December 2020 and the annual and on-appointment grant awards made between 6 September 2022 and 9 May 2023. The illustrative amount is calculated in terms of the number of LTIs x Corporate performance target achieved where relevant (between 84% and 96%) x June 2025 average share price. The actual vesting date for the awards is between 6 September 2025 and 9 May 2026 subject to the company being in an open period. Dividend equivalents accrue at the end of the vesting period, to the extent that the LTIs vest. 50% of the vested LTIs and accrued dividends will be released in 2026 and the balance in 2028, subject to the rules of the LTI plan. As there are no further performance conditions attached to the balance of the 50%, the full amount is disclosed in the single figure table.
| 3 | Mr Herrmann was appointed as EVP: Marketing and Sales Energy and Chemicals Southern Africa from 1 April 2024 on a German employment contract, expatriated to South Africa. His salary continues to be paid in Euros. Other Benefits in the prior year include relocation costs from Germany to South Africa. Other Benefits in the current year include accommodation and transportation offered under the Expatriation policy.
| 4 | Ms Mabelane resigned from Sasol on 31 March 2024.
| 5 | Taxable Fringe Benefits include optional security services and private chauffer trips on which fringe benefit tax is levied.
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | SD Pillay3 | ​ | CF Rademan⁴ | ​ | H Wenhold
​ |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024
Prescribed Officers | ​ | R’000 | ​ | R’000 | ​ | R’000 | ​ | R’000 | ​ | R’000 | ​ | R’000
Salary |  | 5 039 |  | 1 192 |  | — |  | 2 314 |  | 6 288 |  | 3 548
Risk and Retirement funding |  | 795 |  | 192 |  | — |  | — |  | 824 |  | 1 039
Vehicle benefit |  | 150 |  | 38 |  | — |  | — |  | — |  | 71
Healthcare |  | 121 |  | 28 |  | — |  | — |  | 121 |  | 75
Taxable fringe benefits5 |  | 11 |  | — |  | — |  | 249 |  | 34 |  | 28
Total salary and benefits |  | 6 116 |  | 1 450 |  | — |  | 2 563 |  | 7 267 |  | 4 761
Annual short-term incentive1 |  | 3 072 |  | 422 |  | — |  | 1 624 |  | 3 439 |  | 1 378
Long-term incentive gains² |  | 947 |  | 778 |  | — |  | — |  | 671 |  | 3 791
Total annual remuneration |  | 10 135 |  | 2 650 |  | — |  | 4 187 |  | 11 377 |  | 9 930
| 1 | Short-term incentives approved based on the Group results for 2025 and payable in the 2026 financial year. Incentives are calculated as a percentage of total guaranteed package/base salary as at 30 June 2025 x role category % x [(Group STI achievement x 80%) + (Individual Performance Achievement x 20%)] – fatality penalty.
| 2 | Long-term incentives gains for 2025 includes the Restricted LTI awards made on 4 December 2020 and the annual and on-appointment grant awards made between 6 September 2022 and 9 May 2023. The illustrative amount is calculated in terms of the number of LTIs x Corporate performance target achieved where relevant (between 84% and 96%) x June 2025 average share price. The actual vesting date for the awards is between 6 September 2025 and 9 May 2026 subject to the company being in an open period. Dividend equivalents accrue at the end of the vesting period, to the extent that the LTIs vest. 50% of the vested LTIs and accrued dividends will be released in 2026 and the balance in 2028, subject to the rules of the LTI plan. As there are no further performance conditions attached to the balance of the 50%, the full amount is disclosed in the single figure table.
| 3 | Dr Pillay was appointed as EVP: Business Building, Strategy and Technology from 1 April 2024.
| 4 | Mr Rademan’s contract employment as EVP: Sasol Mining ended on 31 October 2023.
| 5 | Taxable Fringe Benefits include optional security services and private chauffer trips on which fringe benefit tax is levied.
Prescribed Officers’ unvested LTI holdings (number and intrinsic value) for 2025 ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | V Bester6 | ​ | AGM Gerber | ​ | C Herrmann
​ | ​ | ​ | ​ | Intrinsic | ​ | ​ | ​ | Intrinsic | ​ | ​ | ​ | Intrinsic
​ | ​ | Number | ​ | value1 | ​ | Number | ​ | value1 | ​ | Number | ​ | value1
Prescribed Officers |  | ​ |  | R’000 |  | ​ |  | R’000 |  | ​ |  | US$’000
Balance at beginning of the year |  | 20 927 |  | 2 890 |  | — |  | — |  | 58 840 |  | 597
Awards granted2 |  | 60 437 |  | 8 941 |  | 85 378 |  | 709 |  | 70 611 |  | 587
Change in value1 |  | — |  | (5 343) |  | — |  | (332) |  | — |  | (597)
Effect of corporate performance targets |  | (351) |  | (35) |  | — |  | — |  | (696) |  | (5)
Dividend equivalents |  | 2 864 |  | 283 |  | — |  | — |  | 3 007 |  | 23
Awards settled3 |  | (6 262) |  | (623) |  | — |  | — |  | (9 741) |  | (66)
Balance at the end of the year4 |  | 77 615 |  | 6 113 |  | 85 378 |  | 377 |  | 122 021 |  | 539
| 1 | Intrinsic values at the beginning and end of the year have been determined using the closing price of:
30 June 2025 R78,76 ($4,42) 30 June 2024 R138,10 ($10,14) Change in intrinsic value for the year results from changes in share price.
| 2 | LTIs granted on 26 August 2024. On appointment awards for Dr Pillay and Ms Gerber was combined with the annual award as they could not be made in May 2024, due to them being placed in a precautionary closed period.
| 3 | Long-term incentives settled represent long-term incentives that vested with reference to the group results for 2024 that was settled in the 2025 financial year. The difference between the long-term incentive gains disclosed in 2024 and the amount settled in 2025 is due to difference in actual share price at vesting date and the share price at date of disclosure.
| 4 | Includes a total of 12 565 award issued in FY21 for which the renewable energy CPT has been deferred up to 31 December 2026.
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | CK Mokoena |  | S Pillay | ​ | H Wenhold
​ |  | Number |  | Intrinsic value1 |  | Number |  | Intrinsic value1 |  | Number |  | Intrinsic value1
Prescribed Officers | ​ | ​ | ​ | R’000 | ​ | ​ | ​ | R’000 |  | ​ |  | R’000
Balance at beginning of the year |  | 127 621 |  | 17 624 |  | 20 178 | ​ | 2 787 | ​ | 105 070 |  | 14 510
Awards granted2 |  | 54 144 |  | 8 010 |  | 53 927 | ​ | 7 978 | ​ | 39 608 |  | 5 860
Change in value1 |  | — |  | (11 369) |  | — | ​ | (4 728) | ​ | — |  | (8 498)
Effect of corporate performance targets |  | (2 810) |  | (277) |  | (208) | ​ | (21) | ​ | (706) |  | (70)
Dividend equivalents |  | 6 282 |  | 620 |  | 1 440 | ​ | 142 | ​ | 9 366 |  | 925
Awards settled3 |  | (22 268) |  | (1 773) |  | (6 306) | ​ | (721) | ​ | (30 240) |  | (3 032)
Balance at the end of the year4 |  | 162 969 |  | 12 835 |  | 69 031 | ​ | 5 437 | ​ | 123 098 |  | 9 695
| 1 | Intrinsic values at the beginning and end of the year have been determined using the closing price of:
30 June 2025 R78,76 ($4,42) 30 June 2024 R138,10 ($10,14) Change in intrinsic value for the year results from changes in share price.
| 2 | LTIs granted on 26 August 2024. On appointment awards for Dr Pillay and Ms Gerber was combined with the annual award as they could not be made in May 2024, due to them being placed in a precautionary closed period.
| 3 | Long-term incentives settled represent long-term incentives that vested with reference to the group results for 2024 that was settled in the 2025 financial year. The difference between the long-term incentive gains disclosed in 2024 and the amount settled in 2025 is due to difference in actual share price at vesting date and the share price at date of disclosure.
| 4 | Includes a total of 12 565 award issued in FY21 for which the renewable energy CPT has been deferred up to 31 December 2026.
Non-executive Directors’ remuneration
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  |  |  |  |  |  |  | Ad Hoc or |  |  |  |
​ | ​ | ​ | ​ | Lead | ​ | ​ | ​ | special | ​ | ​ | ​ | ​
​ | ​ | Board | ​ | independent | ​ | ​ | ​ | purpose | ​ | ​ | ​ | ​
​ | ​ | meeting | ​ | Director | ​ | Committee | ​ | board | ​ | Total1 | ​ | Total1
​ | ​ | fees2 | ​ | fees2 | ​ | fees2 | ​ | committee2 | ​ | 2025 | ​ | 2024
Non-executive Directors | ​ | R’000 | ​ | R’000 | ​ | R’000 | ​ | R’000 | ​ | R’000 | ​ | R’000
SA Nkosi3 |  | — |  | — |  | — |  | — |  | — |  | 1 936
MBN Dube (Chairman)4 |  | 6 671 |  | — |  | — |  | — |  | 6 671 |  | 4 268
S Westwell5 |  | — |  | — |  | — |  | — |  | — |  | 5 612
M Flöel (Lead Independent Director)6 |  | 2 221 |  | 744 |  | 1 269 |  | — |  | 4 234 |  | 3 543
K Harper7 |  | 2 203 |  | — |  | 883 |  | — |  | 3 086 |  | 3 109
DGP Eyton8 |  | 1 935 |  | — |  | 1 154 |  | — |  | 3 089 |  | —
MJ Cuambe9 |  | 1 933 |  | — |  | 673 |  | — |  | 2 606 |  | 2 685
A Schierenbeck10 |  | — |  | — |  | — |  | — |  | — |  | 975
GMB Kennealy |  | 1 957 |  | — |  | 1 025 |  | — |  | 2 982 |  | 2 723
S Subramoney |  | 1 957 |  | — |  | 607 |  | — |  | 2 564 |  | 2 338
TJ Cumming11 | ​ | 1 957 | ​ | — | ​ | 960 | ​ | — | ​ | 2 917 | ​ | 217
NNA Matyumza12 | ​ | 321 | ​ | — | ​ | 100 | ​ | — | ​ | 421 | ​ | 2 338
MEK Nkeli13 |  | 321 |  | — |  | 137 |  | — |  | 458 |  | 2 547
Total |  | 21 476 |  | 744 |  | 6 808 |  | — |  | 29 028 |  | 32 291
​
| 1 | Fees exclude VAT.
| 2 | Board and Committee fees are based in USD, thus impacted by the USD/ZAR foreign exchange rates as determined from time to time. For non-Executive Directors permanently residing outside of the UK, Europe and North America, effective 1 January 2024, the exchange rate from US$to the currency paid in, was fixed for the following 12 month period using the average exchange rate from July 2022 to October 2023. Effective 1 January 2025, the exchange rate was fixed for the period using the average exchange rate from July 2023 to December 2024. A cost-of-living factor is also applied to the fees for these directors.
| 3 | Mr Nkosi resigned from the Board, effective 10 November 2023.
| 4 | Ms Dube was appointed as Chairman of the Sasol Limited Board, effective 13 September 2024.
| 5 | Mr Westwell retired from the Board effective 1 June 2024.
| 6 | Dr Flöel was appointed as Lead Independent Director effective 13 September 2024.
| 7 | Ms Harper was appointed as member of Remuneration Committee effective 14 September 2024. Ms Harper was a member of the Capital Investment Committee until 30 April 2025 and received a pro rata portion of the Committee fee in Q4 FY25.
​
| 8 | Mr Eyton was appointed as a Sasol Limited NED and member of the Capital Investment, Remuneration and Safety, Social & Ethics Committees, effective 1 September 2024 and received a pro rata portion of the Board and Committee fees in Q1 FY25. Mr Eyton was appointed as the Chairman of the Safety, Social & Ethics Committee and member of the Audit Committee, effective 14 September 2024.
| 9 | Mr Cuambe was a member of the Capital Investment Committee until 30 April 2025 and was appointed as a member of the Nomination Governance Committee effective 1 May 2025. The Q4 FY25 payment was pro rated accordingly for these Committee memberships. Mr Cuambe was appointed as the Chairman of the Capital Investment Committee, effective 6 June 2025.
| 10 | Mr Schierenbeck resigned from the Board effective 31 October 2023.
| 11 | Mr Cumming was appointed as the Chairman of the Remuneration Committee and member of the Nomination Governance Committee, effective 1 September 2024. A pro rata portion of the Remuneration Committee member, Remuneration Committee Chair and Nomination Governance Committee fees were paid in Q1 FY25. Mr Cumming was a member of the Capital Investment Committee until 30 April 2025 and received a pro rata portion of the Committee fee in Q4 FY25. Mr Cumming resigned from the Sasol Limited Board on 6 June 2025.
| 12 | Ms Matyumza retired from the Board effective 8 September 2024. A pro rata portion of the Board and Committee fees were paid in Q1 FY25.
| 13 | Ms Nkeli retired from the Board effective 31 August 2024. A pro rata portion of the of Board and Committee fees were paid in Q1 FY25.

X
- Definition The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration